Clinical Trial Update: Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/2 multicenter dose-escalation study of DCR-MYC in hepatocellular carcinoma was terminated, with results posted in September 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• DCR-MYC

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-09-04